linjc16/ctgov huggingface dataset:
Acute Effects of Exercise in Women With Fibromyalgia (FM)

Study Overview
=================
Brief Summary
-----------------
The investigators previous studies of aerobic exercise in women with fibromyalgia (FM) have shown that exercise improves body functions and/or symptom severity in most patients, but not in all. About a third of patients with FM have been shown to have low levels of IGF-1. The purpose of this project is to study individual and biological factors that interact with outcomes of short-term (acute) exercise in FM. Method. A controlled prospective exercise study. Thirty women with FM and 30 healthy age-matched women, aged 20-50 years, will be recruited to the study. Two 15-minute ergometer bicycle exercise tests will be conducted in feasting patients, separated by one month. The first exercise test is at a low and the second at a high intensity. Measurements comprise blood test, pain rating and pain threshold, conducted before and after the test. The levels of IGF-1, IL-6 and IL-8 will be measured, and the changes in them will be related to health status and pain.

Official Title
-----------------
Acute Effects of Exercise in Women With FM

Conditions
-----------------
Fibromyalgia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of fibromyalgia age 20-50 years Exclusion Criteria: heart disease neurological disease severe osteoarthritis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Fibromyalgia<br>Women with fibromyalgia, aged 20-50 years | |
| Healthy controls<br>Women without severe disease, aged 20-50 years | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IGF1 level | Ergometer cycle test of 15 minutes at low respective high intensity. Blood test is done before and after exercise. Change in quantity of IGF1 is measured. | 15 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain rating | Pain is rated by the test person before and after the ergometer cycle test. | 15 minutes | 
| Pain threshold | Pain threshold is measured before and after the ergometer test. | 15 minutes | 
| Interleukin 6 and 8 | Blood test is done before and after the ergometer bicycle test. Quantity of interleukin 6 and 8 is measured. | 15 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fibromyalgia, Pain, Women, Exercise, IGF1
Study of Descartes-30 in Acute Respiratory Distress Syndrome

Study Overview
=================
Brief Summary
-----------------
Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19

Official Title
-----------------
Phase I/IIA Study of Descartes-30 in Acute Respiratory Distress Syndrome

Conditions
-----------------
Covid19, Acute Respiratory Distress Syndrome

Intervention / Treatment
-----------------
* Biological: Descartes 30


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be 18 years of age or older at the time of enrollment Patient maintains a diagnosis of moderate or severe ARDS according to the Berlin definition of ARDS Exclusion Criteria: Patient is currently enrolled into another therapeutic clinical trial with an experimental therapy that has not received marketing approval by U.S. FDA. Patient is in moribund state with expected survival <24 hours.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Descartes 30<br> | Biological: Descartes 30<br>* Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the safety of Descartes-30 in patients with moderate-to-severe ARDS. | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 2 years |
Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids

Study Overview
=================
Brief Summary
-----------------
The long-term outcomes of branched-chain amino acid (BCAA) administration in patients undergoing hepatic resection remain unclear. The aim of this study is to assess the impact of oral supplementation with BCAA on the prevention for the development of liver tumorigenesis in patients undergoing liver resection.

Detailed Description
-----------------
This study might demonstrate a tendency of the improvement in the cumulative tumor recurrence rate after hepatectomy for liver neoplasm in the Livact group compared to that in the Control Group. The investigators believe that BCAA seems to be a remarkable benefit for liver resection, especially on its reduction in the recurrence of liver cancer. This treatment regimen has potential to offer benefits for clinical use selectively, especially for patients with chronic liver diseases.

Official Title
-----------------
The Evaluation About the Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids

Conditions
-----------------
Liver Cancer

Intervention / Treatment
-----------------
* Drug: LIVACT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: These patients were scheduled for elective liver resection to treat hepatocellular carcinoma or adenocarcinoma of the liver. Exclusion Criteria: a body-weight loss greater than 10% during the 6 months prior to surgery, the presence of distant metastases, or serious impairment of organ function due to respiratory, renal, or heart disease.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>normal dietary | |
| No Intervention: LIVACT<br>The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance. | Drug: LIVACT<br>* LIVACT contains 13.0 g of free amino acids<br>* Other names: branched-chain amino acid;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative tumor recurrence rate |  | 5 years follow up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| nutritional status | The secondary endpoint was a comparison of measurements of body weight, arm muscle circumference (AMC) between patient groups. | 5 years follow up |
Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials

Study Overview
=================
Brief Summary
-----------------
The present study conducted a meta-analysis of 22 randomly controlled trials to assess the effects of soluble fiber intake on blood pressure in human subjects. Using the Cochrane Handbook for Systematic Reviews of Intervention, a systematic review and meta-analysis was conducted. Information regarding study methods, characteristics, mean BP and standard deviations were extracted The data from each study were pooled using a random effects model to estimate the effects of soluble fiber consumption on blood pressure.

Official Title
-----------------
Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials

Conditions
-----------------
Blood Pressure

Intervention / Treatment
-----------------
* Dietary Supplement: Soluble Fibre


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Randomized Controlled Trials Parallel or Crossover Design Duration: >3 weeks Human trials Viscous (soluble) fiber Viable endpoint data Articles published in English Exclusion Criteria: Non-human Non-randomized Lack of control Less than 4 weeks in duration No viable endpoint data
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: Soluble Fibre|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systolic Blood Pressure |  | 4 weeks | 
| Diastolic Blood Pressure |  | 4 weeks |
Medical Imaging in the Diagnosis of Ganglion Cysts of the Hand

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate if inexpensive, readily available and portable wireless ultrasound devices can detect ganglion cysts of the wrist and hand in compare to a cart-based ultrasound device before surgery.

Official Title
-----------------
Medical Imaging in the Diagnosis of Ganglion Cysts of the Hand

Conditions
-----------------
Ganglion Cyst of Both Hands

Intervention / Treatment
-----------------
* Device: Portable wireless ultrasonography devices
* Device: Cart-based ultrasonography device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Flexor tendon sheath ganglion cyst Dorsal ganglion cyst Palmar ganglion cyst Male and female patients minimum age 18 years MRI of the affected area Exclusion Criteria: Pregnancy, lactation Malignant disease Insufficient mental possibility of cooperation Medical, psychiatric or other conditions that restrict the patient's following abilities: to interpret the study information, to give informed consent, to adhere to the rules of the protocol, or to complete the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Suspected ganglion cyst of the wrist or hand<br>Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging AND cart-based ultrasound imaging before surgery. | Device: Portable wireless ultrasonography devices<br>* Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging<br>Device: Cart-based ultrasonography device<br>* Patients with suspected ganglion cyst of the wrist or hand receive conventional cart-based ultrasound imaging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Size and location of ganglion cysts of the wrist and hand | Assessment of size in cm and location of the ganglion cyst of the wrist or hand by pre-surgery wireless ultrasound in compare to pre-surgery cart-based ultrasound | Baseline (pre-surgery) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MRI measure of size and location of ganglion cysts of the wrist and hand | Assessment of size in cm and location of the ganglion cyst of the wrist or hand by pre-surgery MRI in compare to pre-surgery ultrasonography | Baseline (pre-surgery) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Portable ultrasound, Diagnostics, Mobile ultrasound, Hand held ultrasound, Wireless ultrasound
Refractory Status Epilepticus Treatment: Quality and Efficacy of Coma Induction

Study Overview
=================
Brief Summary
-----------------
This study is to investigate the effects of different treatment characteristics regarding the use of intravenous anesthetic drugs (IVADs) as a rescue treatment for refractory Status epilepticus (RSE) on course and outcome. A retrospective data extraction from the digital medical records, the electroencephalographic and microbiologic database of all consecutive adult patients with Status epilepticus (SE) admitted to the University Hospital Basel is undertaken.

Official Title
-----------------
Refractory Status Epilepticus Treatment (RESET): Quality and Efficacy of Coma Induction

Conditions
-----------------
Status Epilepticus, Refractory Status Epilepticus

Intervention / Treatment
-----------------
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed SE between 2005 and 2019 who have been treated at intensive care units (ICUs) of the University Hospital of Basel Exclusion Criteria: Patients with repetitive epileptic seizures not qualifying for SE or RSE Patients with documented refusal of the general in-house consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Data collection|collection of patient data Data collection (demographics, prehospital management, duration of ICU and hospital stay, destination at discharge, date(s) of seizure(s), electroencephalographic (EEG) data, seizure history and etiology, number and duration of SE episodes, medication, types of SE according to the current guidelines from the International League of Epilepsy (ILAE), neuroimaging features, comorbidities, laboratory parameters, complications during and after SE , laboratory testing, vital signs, fluid balance) will be performed from the digital medical records, the electroencephalographic and microbiologic database of patients|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of in- hospital death | number of in- hospital death | at baseline (T0) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| neurofunctional alteration assessed by Glasgow Outcome Score (GOS) | neurofunctional alteration assessed by Glasgow Outcome Score (GOS). The Glasgow Outcome Scale (GOS) is a global scale for functional outcome that rates patient status into one of five categories: Dead, Vegetative State, Severe Disability, Moderate Disability or Good Recovery | at baseline (T0) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
artificial deep coma, intravenous anesthetic drugs (IVADs), total seizure oppression
Renal Artery Calcium and Hypertension

Study Overview
=================
Brief Summary
-----------------
CT of the abdomen is a very common examination performed for various indications.One of the common findings is vascular calcifications including calcifications of the renal arteries.Calcifications in the carotid arteries and coronary arteries are good predictor for obstructive atherosclerotic disease.Stenosis of the renal arteries can cause symptomatic or asymptomatic hypertension with subsequent clinical sequelae. Therefore early diagnosis of this condition is imperative. The goal of our study is to investigate the correlation between incidental calcifications of the renal arteries in CT examinations and the presence of actual stenosis of these vessels in patients with and without hypertension.

Detailed Description
-----------------
Every patient aged 30-100 referred for abdominal CT examination with IV contrast injection will be included in this study (total 300 patients.Prior to the examination relevant clinical data including history of hypertension and predisposing conditions for atherosclerotic disease, will be investigated. The patient will undergo conventional CT with no special procedures. The images will be review by the radiologist for the presence of renal arteries calcifications, renal arteries stenosis,plaque location, plaque burden and characterization and secondary renal pathology. This study will not change the examination technique and is not associated with any inconvenience to the patients.

Official Title
-----------------
Calcifications of the Renal Arteries and Renal Artery Stenosis in Patients With and Without Hypertension?

Conditions
-----------------
Hypertension, Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Every patient referred fo abdominal CT aged 30-100 Exclusion Criteria: Contraindication for IV contrast injection failure to demonstrate renal arteries with contrast refusal to sign an informed consent

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
renal artery, calcium, CT, hypertension
Diabetes Outcomes in COVID-19 Pandemic

Study Overview
=================
Brief Summary
-----------------
Diabetes management and follow-up has become a challenge during the COVID-19 pandemic. Nation-wide lockdowns and social distancing measures adopted in an attempt to break the chain of COVID-19 transmission have significantly disrupted routine care and follow-up of diabetes. In the health sector, especially in low-income countries such as Pakistan, there has been a shift of resources and staff reassignment from stable chronic illnesses to support COVID-19 pandemic. Disruption of routine outpatient health services and travel restrictions increase the risk of worsening diabetes control and diabetes-related health outcomes. Additionally, social isolation amidst an atmosphere of fear and uncertainty contributes to stress further affecting glycaemic control.

Detailed Description
-----------------
An observational cross-sectional study was conducted using telephone interview method in Diabetes Management Centre (DMC), Services hospital, Lahore. The study participants were 1282 diabetic patients selected randomly from electronic medical record (EMR) database of the Centre. A structured questionnaire was used to evaluate parameters which included patients' demographic information; diabetes self-care and general health profile; COVID-related questions and its impact on quality of life (QoL); financial and social support issues.

Official Title
-----------------
Health-related Outcomes and Behaviour Changes in a Cohort of Diabetic Population During COVID-19 Pandemic: Results of a Telephonic Survey

Conditions
-----------------
Diabetes, Covid19, Isolation, Social

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 1 and type 2 diabetic patients registered with Diabetes Management Centre, Services hospital, Lahore, Pakistan. Exclusion Criteria: Patients lacking telephonic contact or with invalid contact numbers.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | Death due to diabetes-related complications or otherwise | during 3months of lockdown | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| COVID-19 illness | %age of participants with one or more symptoms of fever, sore throat, cough, dyspnoea | During 3months of lockdown | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, diabetes mellitus, telesurvey
Primary Prevention of Cardiovascular Diseases in Childhood and Adolescence: the Role of Physical Activity

Study Overview
=================
Brief Summary
-----------------
This research project is about a physical activity intervention in pediatric outpatients to try control and prevent heart diseases such as hypertension, obesity, high cholesterol.

Detailed Description
-----------------
Control Group: receive information about health lifestyle Interventional Group: receive a structured plan with exercises to do 3 times per week within 50 minutes. It is a randomized clinical trial and population are children and adolescents.

Official Title
-----------------
Outpatient Strategy of Primary Prevention of Cardiovascular Diseases in Childhood and Adolescence: the Role of Physical Activity

Conditions
-----------------
Obesity, Hypercholesterolemia, High Blood Pressure, Sedentary Lifestyle

Intervention / Treatment
-----------------
* Other: physical exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 6 to 17 years obesity high cholesterol Exclusion Criteria: congenital heart diseases less than 6 or more than 17 years old

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>Participants do not receive a physical exercise plan. Participants receive a simple orientations about lifestyle activities. | |
| Experimental: Exercise<br>Participants receive a physical exercise plan to play at home | Other: physical exercise<br>* 150 minutes per week<br>* Other names: exercise;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction on risk factors for a cardiovascular diseases (reduction on BMI, cholesterol, LDL, glucose, high-sensitivity C-reactive protein, blood pressure and/or increase on HDL) | These measurement (taken at end of study) are assessed for a external research (blind for randomization) to judge the individual outcome. | These measurement were taken at end of followup (27th week) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obesity, cholesterol, cholesterol, LDL, cholesterol, HDL, blood glucose, Triglyceride, C-Reactive Protein - hs, blood pressure, physical activity, Sedentary Lifestyle